Notice: This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends RTRX vs. PBH, CRNX, APLS, PTCT, RNA, RYTM, PRGO, ACAD, XENE, and MLTXShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Prestige Consumer Healthcare (PBH), Crinetics Pharmaceuticals (CRNX), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Rhythm Pharmaceuticals (RYTM), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Xenon Pharmaceuticals (XENE), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "medical" sector. Travere Therapeutics vs. Prestige Consumer Healthcare Crinetics Pharmaceuticals Apellis Pharmaceuticals PTC Therapeutics Avidity Biosciences Rhythm Pharmaceuticals Perrigo ACADIA Pharmaceuticals Xenon Pharmaceuticals MoonLake Immunotherapeutics Travere Therapeutics (NASDAQ:RTRX) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, community ranking, earnings, dividends, media sentiment, risk and analyst recommendations. Which has stronger earnings & valuation, RTRX or PBH? Prestige Consumer Healthcare has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$175.34M5.67-$146.43M-$3.46-5.62Prestige Consumer Healthcare$1.13B3.48$209.34M$4.1119.31 Does the MarketBeat Community prefer RTRX or PBH? Prestige Consumer Healthcare received 71 more outperform votes than Travere Therapeutics when rated by MarketBeat users. However, 73.17% of users gave Travere Therapeutics an outperform vote while only 70.34% of users gave Prestige Consumer Healthcare an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes42073.17% Underperform Votes15426.83% Prestige Consumer HealthcareOutperform Votes49170.34% Underperform Votes20729.66% Does the media prefer RTRX or PBH? In the previous week, Prestige Consumer Healthcare had 13 more articles in the media than Travere Therapeutics. MarketBeat recorded 14 mentions for Prestige Consumer Healthcare and 1 mentions for Travere Therapeutics. Prestige Consumer Healthcare's average media sentiment score of 0.27 beat Travere Therapeutics' score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prestige Consumer Healthcare 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is RTRX or PBH more profitable? Prestige Consumer Healthcare has a net margin of 18.54% compared to Travere Therapeutics' net margin of -49.13%. Prestige Consumer Healthcare's return on equity of 12.23% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-49.13% -36.38% -14.90% Prestige Consumer Healthcare 18.54%12.23%6.14% Do insiders & institutionals have more ownership in RTRX or PBH? 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 4.6% of Travere Therapeutics shares are owned by insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, RTRX or PBH? Travere Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Do analysts rate RTRX or PBH? Prestige Consumer Healthcare has a consensus price target of $85.25, suggesting a potential upside of 7.42%. Given Prestige Consumer Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prestige Consumer Healthcare 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryPrestige Consumer Healthcare beats Travere Therapeutics on 14 of the 18 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$993.47M$6.53B$5.38B$9.10BDividend YieldN/A2.96%5.37%3.99%P/E Ratio-9.225.0161.9313.82Price / Sales5.67341.071,263.6782.69Price / CashN/A64.2843.7436.83Price / Book3.785.074.964.69Net Income-$146.43M$154.90M$117.89M$224.57M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$19.46+5.9%N/A+110.2%$993.47M$175.34M-9.22221High Trading VolumePBHPrestige Consumer Healthcare3.2494 of 5 stars$74.64+0.9%$85.25+14.2%+33.3%$3.69B$1.11B18.16540CRNXCrinetics Pharmaceuticals3.6225 of 5 stars$38.98-4.0%$74.40+90.9%+9.2%$3.61B$1.04M-10.45210Analyst RevisionGap UpAPLSApellis Pharmaceuticals4.4056 of 5 stars$28.59+4.2%$46.65+63.2%-52.8%$3.56B$715.22M-14.08770Analyst ForecastInsider TradeShort Interest ↑News CoveragePTCTPTC Therapeutics4.0004 of 5 stars$44.05+0.3%$54.08+22.8%+67.2%$3.40B$900.66M-7.421,410Analyst RevisionRNAAvidity Biosciences1.1793 of 5 stars$28.41-3.6%$65.80+131.6%+203.5%$3.39B$10.12M-9.86190Analyst ForecastAnalyst RevisionNews CoverageRYTMRhythm Pharmaceuticals4.2039 of 5 stars$54.89-2.3%$68.09+24.0%+40.2%$3.37B$112.53M-12.68140PRGOPerrigo4.9455 of 5 stars$24.33-0.2%$35.00+43.9%-26.2%$3.32B$4.39B-20.799,140ACADACADIA Pharmaceuticals3.9071 of 5 stars$17.90+3.7%$25.25+41.1%-34.4%$2.98B$929.24M22.95510XENEXenon Pharmaceuticals2.7705 of 5 stars$38.25-0.4%$56.00+46.4%-10.9%$2.92B$9.43M-13.56210Positive NewsMLTXMoonLake Immunotherapeutics1.9309 of 5 stars$45.26-2.3%$81.43+79.9%-14.4%$2.89BN/A-35.092 Related Companies and Tools Related Companies Prestige Consumer Healthcare Alternatives Crinetics Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives PTC Therapeutics Alternatives Avidity Biosciences Alternatives Rhythm Pharmaceuticals Alternatives Perrigo Alternatives ACADIA Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RTRX) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RTRX Stock Alerts